| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $417,410 | 2 | 100 |
| Mayo Stephen | director | 0 | $0 | 1 | $123,208 | $-123,208 |
| Estepan Ian Michael | Chief Operating Officer | 0 | $0 | 1 | $294,202 | $-294,202 |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS …
Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $0 and sold $417,410 worth of Sarepta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $8.3M and sold $4.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.
| 2026-03-12 | Sale | Mayo Stephen | director | 7,239 0.0069% | $17.02 | $123,208 | +6.92% | |
| 2025-12-16 | Sale | Estepan Ian Michael | Chief Operating Officer | 13,187 0.0135% | $22.31 | $294,202 | -16.54% | |
| 2025-03-12 | Sale | Nicaise Claude | director | 2,491 0.0026% | $99.64 | $248,203 | -78.82% | |
| 2024-12-12 | Sale | Wigzell Hans Lennart Rudolf | director | 10,500 0.011% | $124.84 | $1.31M | -80.45% | |
| 2024-12-05 | Sale | Boor Kathryn Jean | director | 1,636 0.0017% | $125.55 | $205,400 | -71.31% | |
| 2024-08-30 | Sale | Estepan Ian Michael | Chief Financial Officer | 5,985 0.0063% | $137.36 | $822,100 | -24.10% | |
| 2024-08-16 | Chambers Michael Andrew | director | 37,038 0.0404% | $133.80 | $4.96M | -19.86% | ||
| 2024-06-25 | Sale | Arif Bilal | Chief Tech Ops Officer | 3,898 0.0043% | $163.23 | $636,271 | -24.72% | |
| 2024-06-25 | Sale | Brown Ryan Edward | EVP, General Counsel | 38,957 0.0421% | $161.61 | $6.3M | -24.72% | |
| 2024-06-24 | Sale | Arif Bilal | Chief Tech Ops Officer | 7,859 0.0083% | $163.08 | $1.28M | -27.32% | |
| 2024-05-02 | Sale | Murray Dallan | Chief Customer Officer | 3,635 0.0041% | $140.00 | $508,900 | -5.14% | |
| 2024-03-11 | Sale | Boor Kathryn Jean | director | 761 0.0008% | $122.93 | $93,550 | +3.09% | |
| 2024-03-08 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0159% | $123.25 | $1.85M | +0.78% | |
| 2024-03-05 | Sale | Mayo Stephen | director | 3,135 0.0033% | $122.96 | $385,480 | +2.03% | |
| 2024-03-01 | Sale | Estepan Ian Michael | Chief Financial Officer | 1,200 0.0013% | $128.30 | $153,960 | -2.59% | |
| 2024-03-01 | Sale | Brown Ryan Edward | EVP, General Counsel | 2,000 0.0021% | $125.34 | $250,680 | -2.59% | |
| 2024-03-01 | Sale | Arif Bilal | Chief Tech Ops Officer | 2,000 0.0021% | $128.84 | $257,676 | -2.59% | |
| 2023-11-03 | INGRAM DOUGLAS S | President & CEO | 25,225 0.0275% | $79.36 | $2M | +60.46% | ||
| 2023-11-03 | Barry Richard | director | 50,000 0.0542% | $78.81 | $3.94M | +60.46% | ||
| 2023-08-14 | Chambers Michael Andrew | director | 9,979 0.0104% | $109.47 | $1.09M | +7.99% |
| HAYWOOD GEORGE WEAVER | 8213717 7.7762% | $152.28M | 16 | 0 | <0.0001% | |
| INGRAM DOUGLAS S | President & CEO | 390307 0.3695% | $7.24M | 7 | 0 | +25.87% |
| Chambers Michael Andrew | director | 284034 0.2689% | $5.27M | 5 | 0 | +5.28% |
| Barry Richard | director | 140000 0.1325% | $2.6M | 7 | 3 | +30.38% |
| BEHRENS M KATHLEEN | director | 130517 0.1236% | $2.42M | 6 | 2 | +42.52% |
| BOYLE J DAVID II | CEO | 70282 0.0665% | $1.3M | 2 | 0 | +60.55% |
| Rodino-Klapac Louise | Head of R&D, CSO | 65678 0.0622% | $1.22M | 1 | 0 | +1.95% |
| Kaye Edward M. MD | director | 52471 0.0497% | $972,812.34 | 1 | 4 | |
| Price Ben Gil | director | 42830 0.0405% | $794,068.20 | 10 | 0 | +41.98% |
| CHASE ANTHONY R | director | 41744 0.0395% | $773,933.76 | 9 | 4 | +41.16% |
| Mahatme Sandesh | EVP, CFO & CBO | 30179 0.0286% | $559,518.66 | 1 | 7 | |
| Christopher Nishan Garabedian | President and CEO | 29552 0.028% | $547,894.08 | 3 | 0 | <0.0001% |
| BONNEY MICHAEL W | director | 7051 0.0067% | $130,725.54 | 1 | 0 | +39.82% |
$607,395,062 | 99 | 4.23% | $1.88B | |
$21,345,882 | 83 | 94.45% | $2.19B | |
Sarepta Therapeutics, Inc. (SRPT) | $47,419,530 | 58 | 17.20% | $1.96B |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B |
| Increased Positions | 209 | +61.83% | 20M | +22.73% |
| Decreased Positions | 146 | -43.2% | 15M | -17.29% |
| New Positions | 72 | New | 3M | New |
| Sold Out Positions | 52 | Sold Out | 4M | Sold Out |
| Total Postitions | 401 | +18.64% | 94M | +5.44% |
| Blackrock, Inc. | $281,289.00 | 12.57% | 13.2M | +1M | +8.95% | 2025-09-30 |
| Vanguard Group Inc | $230,520.00 | 10.3% | 10.82M | +2M | +18.09% | 2025-09-30 |
| State Street Corp | $113,048.00 | 5.05% | 5.3M | +609,880 | +12.99% | 2025-09-30 |
| Erste Asset Management Gmbh | $57,237.00 | 2.56% | 2.69M | +1M | +65.65% | 2025-09-30 |
| Renaissance Technologies Llc | $56,475.00 | 2.52% | 2.65M | +2M | +324.38% | 2025-09-30 |
| Two Sigma Investments, Lp | $45,556.00 | 2.04% | 2.14M | -23,933 | -1.11% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $42,770.00 | 1.91% | 2.01M | -2M | -55.19% | 2025-09-30 |
| Ubs Group Ag | $42,418.00 | 1.9% | 1.99M | +1M | +297.24% | 2025-09-30 |
| Aberdeen Group Plc | $42,253.00 | 1.89% | 1.98M | +740,360 | +59.59% | 2025-09-30 |
| Two Sigma Advisers, Lp | $41,726.00 | 1.87% | 1.96M | -27,700 | -1.4% | 2025-09-30 |